Compare Entegris Inc (ENTG) vs Johnson & Johnson (JNJ) Price & Performance

ENTG trades at $162.19, down 2.48% today, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 29, 2026. Revenue for 2025 was $3.20B, with a net income margin of 7.37%. Analyst consensus is strongly bullish, with a price target of $182.43, indicating a 12.5% upside. Recent news highlights strong AI-driven semiconductor demand and institutional buying interest.

The outlook for ENTG is positive, supported by robust earnings performance and growing demand in the semiconductor sector. Key opportunities include expansion in AI-related markets and operational efficiency gains. Risks involve high valuation multiples, competitive pressures, and sensitivity to semiconductor industry cycles. Investors should weigh the strong analyst support against potential market volatility and execution challenges.

Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.

JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.